Marizyme, Inc. Appoints Julie Kampf as an Independent Director
February 05, 2021 at 02:00 am IST
Share
On February 3, 2021, the Board of Directors of Marizyme, Inc. appointed Julie Kampf as an independent director. Ms. Kampf will not receive compensation for her services at this time. Julie Kampf is a global business executive and thought leader on talent and diversity, with 30 years of
experience in the life science and retail/consumer fashion industries and on not-for-profit Boards of Directors.
She is currently Chief Executive Officer of JBK Associates International, which she founded in 2003, and has
grown to become a multi-million-dollar company as one of Inc.'s fastest growing private companies, four
consecutive years, beginning in 2011.
Marizyme, Inc. is a medical technology company. The Company is focused on cardiac and surgical care by delivering innovative solutions for coronary artery bypass graft (CABG) surgery and other surgical procedures. Its product DuraGraft, is a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, thereby reducing the incidence and complications of graft failure and improving clinical outcomes post bypass surgery. The Companyâs product under development includes MATLOC and MAR-FG-001. MATLOC is a lab-on-chip digital screening and diagnostic device platform being developed for quantitative chronic kidney disease (CKD) assessment. The MAR-FG-001 is a tumescent solution base for fat grafting procedures that is used for plastic and cosmetic surgeries in which fat is transferred from one area of the body to another to correct a defect, replace injured tissue, or to make cosmetic enhancements.
MARIZYME, INC. 
